AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
14 registrations across 2 African markets— 14 active
Markets with AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| DIPTATRIS 5/160/12.5 TABLET, COATED; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED | active | Mar 2030 |
| DIPTATRIS 10/160/25MG TABLET, COATED; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED | active | Mar 2030 |
| DIPTATRIS 10/160/12.5MG TABLET, COATED; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED | active | Mar 2030 |
| DIPTATRIS 5/160/25 TABLET, COATED; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED | active | Mar 2030 |
| DIPTATRIS 10/320/25MG TABLET, COATED; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED | active | Mar 2030 |
| TRI-VALSAPRESS 5;160;12.5 TABLET, COATED; ORAL | 🇿🇼Zimbabwe | COSPHARM INVESTMENTS PVT LTD | active | Dec 2027 |
| EXFORGE HCT TABLET; ORAL | 🇿🇼Zimbabwe | NOVARTIS PHARMA SERVICES AG | active | Dec 2027 |
| TRI-VALSAPRESS 10; 25 ; 320 TABLET, COATED; ORAL | 🇿🇼Zimbabwe | COSPHARM INVESTMENTS PVT LTD | active | Dec 2027 |
| EXFORGE HCT TABLET; ORAL | 🇿🇼Zimbabwe | NOVARTIS PHARMA SERVICES AG | active | Dec 2027 |
| TRI-VALSAPRESS 10;12.5;160 TABLET, COATED; ORAL | 🇿🇼Zimbabwe | COSPHARM INVESTMENTS PVT LTD | active | Dec 2027 |
| EXFORGE HCT TABLETS | 🇬🇭Ghana | — | active | Dec 2026 |
| EXFORGE HCT TABLETS (Each film coated tablet contains Amlodipine Besylate/Hydrochlorothiazide/Valsartan 10mg/25mg/320mg) | 🇬🇭Ghana | — | active | Dec 2026 |
| EXFORGE HCT TABLETS | 🇬🇭Ghana | — | active | Dec 2026 |
| EXFORGE HCT TABLETS (Each film coated tablet contains Amlodipine Besylate/Hydrochlorothiazide/Valsartan 10mg/25mg/320mg) | 🇬🇭Ghana | — | active | Dec 2026 |
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN in Africa — Regulatory Overview
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN is registered across 2 African markets with 14 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zimbabwe, Ghana. AfricaRegulatory refreshes this data daily from official government sources.
Of the 14 registrations, 14 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.